Gonadotropin Releasing Hormone (GnRH) Agonist Improves Hyperandrogenism in an Adolescent Female with a Novel Insulin Receptor Gene Mutation

Authors

Emily Paprocki, Children's Mercy HospitalFollow
Romina Barral, Children's Mercy HospitalFollow
Heidi Vanden Brink
Maria E. Lujan
Tania S. Burgert, Children's Mercy HospitalFollow

Publication Date

5-2019

Files

Abstract

We describe a case of an adolescent female with Type A insulin resistance whose severe hirsutism and hyperandrogenism were improved with leuprolide, despite extreme hyperinsulinemia. Ovarian volume decreased in association with the resolution of hyperandrogenism, consistent with ovarian size reflecting hyperandrogenism in adolescents.

This case allowed us to examine the frequently debated bidirectional relationship between insulin and hyperandrogenism, often deemed independent of gonadotropin activity.

MeSH Keywords

Insulin Resistance; Hyperandrogenism; Leuprolide; Receptor, Insulin/genetics; Adolescent; Female; Polycystic Ovary Syndrome

Keywords

GnRH agonist; PCOS

Disciplines

Endocrine System Diseases | Endocrinology, Diabetes, and Metabolism | Pediatrics

Notes

Presented at Children's Mercy Research Days, May 2019

Recommended Citation

Paprocki, Emily; Barral, Romina; Vanden Brink, Heidi; Lujan, Maria E.; and Burgert, Tania S., "Gonadotropin Releasing Hormone (GnRH) Agonist Improves Hyperandrogenism in an Adolescent Female with a Novel Insulin Receptor Gene Mutation" (2019). Posters. 102.
https://scholarlyexchange.childrensmercy.org/posters/102